Nomura Asset Management Co. Ltd. cut its stake in Gilead Sciences (NASDAQ:GILD) by 0.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 820,031 shares of the biopharmaceutical company’s stock after selling 1,029 shares during the period. Nomura Asset Management Co. Ltd. owned approximately 0.06% of Gilead Sciences worth $58,748,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Welch Investments LLC purchased a new position in Gilead Sciences in the third quarter valued at approximately $108,000. Wealthcare Advisory Partners LLC purchased a new position in Gilead Sciences in the third quarter valued at approximately $133,000. Horan Capital Advisors LLC. purchased a new position in Gilead Sciences in the third quarter valued at approximately $144,000. Hanson & Doremus Investment Management raised its holdings in Gilead Sciences by 806.5% in the third quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 1,613 shares during the period. Finally, Rational Advisors LLC purchased a new position in Gilead Sciences in the third quarter valued at approximately $170,000. 78.30% of the stock is currently owned by institutional investors and hedge funds.
In other Gilead Sciences news, Chairman John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $83.56, for a total value of $4,178,000.00. Following the completion of the transaction, the chairman now owns 3,046,766 shares of the company’s stock, valued at $254,587,766.96. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP James R. Meyers sold 100,000 shares of Gilead Sciences stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $80.24, for a total transaction of $8,024,000.00. Following the completion of the transaction, the executive vice president now directly owns 102,715 shares of the company’s stock, valued at approximately $8,241,851.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 402,767 shares of company stock valued at $31,911,485. 1.30% of the stock is currently owned by corporate insiders.
A number of research firms have recently issued reports on GILD. Vetr lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 price objective on the stock. in a research note on Wednesday, January 17th. Zacks Investment Research lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, December 27th. Wells Fargo upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $79.02 to $96.00 in a research note on Tuesday, January 16th. Citigroup upgraded shares of Gilead Sciences from a “neutral” rating to a “buy” rating and dropped their price objective for the company from $88.80 to $76.00 in a research note on Tuesday, January 30th. Finally, BidaskClub lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $88.61.
Gilead Sciences stock opened at $75.22 on Monday. The firm has a market capitalization of $98,166.87, a price-to-earnings ratio of 8.79, a price-to-earnings-growth ratio of -1.73 and a beta of 1.19. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.74 and a quick ratio of 2.67. Gilead Sciences has a 12 month low of $63.76 and a 12 month high of $89.54.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 EPS for the quarter, topping analysts’ consensus estimates of $1.67 by $0.11. The firm had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $5.71 billion. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The firm’s revenue was down 18.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.70 earnings per share. analysts anticipate that Gilead Sciences will post 6.21 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 29th. Shareholders of record on Friday, March 16th were issued a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a yield of 3.03%. The ex-dividend date of this dividend was Thursday, March 15th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s payout ratio is currently 26.64%.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/04/16/gilead-sciences-gild-shares-sold-by-nomura-asset-management-co-ltd.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.